Amicus Therapeutics remains a Buy, supported by strong momentum in Galafold and Pombiliti/Opfolda, both with blockbuster potential. FOLD's Galafold leads in Fabry disease as the first oral precision ...

Princeton Professor Robert P. George, a leader of the conservative legal movement and confidant of the judicial activist and Donald Trump ally Leonard Leo, made the case for overturning Roe v. Wade in ...

"I've signed many of them over the years," retired U.S. District Judge Shira Scheindlin said of amicus briefs from former jurists. "But nothing like now. Now, it's like every other week somebody is ...

12/15/2022 Motion for leave to file amici brief filed by Relentless, Inc., et al. 12/15/2022 Motion for leave to file amici brief filed by David Goethel, et al. 12/15/2022 Motion of Advancing American ...

Global net sales of Galafold increased 17% in 2023 to $388 million and Amicus expects 2024 net sales to grow between 11% and 17% based on a constant exchange rate to $430-450 million. Galafold has ...

Holding: The "first sale" doctrine, which allows the owner of a copyrighted work to sell or otherwise dispose of that copy as he wishes, applies to copies of a copyrighted work lawfully made abroad.